Working... Menu

The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02204644
Recruitment Status : Completed
First Posted : July 30, 2014
Last Update Posted : February 27, 2018
Information provided by (Responsible Party):
Jiangsu Hansoh Pharmaceutical Co., Ltd.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2017
  Actual Study Completion Date : December 2017